Delay of dialysis in end-stage renal failure: Prospective study on percutaneous renal artery interventions  by Korsakas, S. et al.
Kidney International, Vol. 65 (2004), pp. 251–258
CLINICAL NEPHROLOGY EPIDEMIOLOGY CLINICAL TRIALS
Delay of dialysis in end-stage renal failure: Prospective study
on percutaneous renal artery interventions
S. KORSAKAS, M.G. MOHAUPT, H.P. DINKEL, F. MAHLER, D.D. DO, J. VOEGELE,
and I. BAUMGARTNER
Swiss Cardiovascular Center, Division of Angiology; Division of Nephrology & Hypertension; and Institute of Diagnostic
Radiology, University Hospital, Bern, Switzerland
Delay of dialysis in end-stage renal failure: Prospective study
on percutaneous renal artery interventions.
Background. Renal artery stenosis (RAS) is a cause of end-
stage renal failure. We studied the effect of percutaneous renal
artery intervention (PRI) in patients with advanced, progressive
disease at risk for renal failure, hypothesizing a beneficial effect.
Methods. Thirty-nine primary and 14 secondary PRIs were
performed on 28 patients with atherosclerotic RAS, serum cre-
atinine >300 lmol/L, and progressive loss of renal function
≥1 year before PRI. Renal function and RA patency were
prospectively followed for 12 months after primary and sec-
ondary PRI. The intervention’s effect on the progressive loss of
renal function was calculated by comparing reciprocal slopes of
serum creatinine against time before and after PRI.
Results. Progression of renal failure slowed significantly fol-
lowing PRI. Mean (±SE) slopes of reciprocal serum creatinine
values were: 6.69 ± 0.97 L lmol−1 day−1 (×10−6) before and
6.76 ± 3.03 L lmol−1 day−1 (×10−6) after PRI (P = 0.0007).
Fifteen patients (53.5%) showed improvement or stabilization
of progressive renal dysfunction. Out of 11 patients expected
to become dialysis dependent within one year, 8 (72.7%) expe-
rienced an improvement in renal function sufficient to remain
dialysis-free. Favorable outcome correlated with a lower creati-
nine level (P = 0.0137) and a more negative slope of progression
(r = 0.49, P = 0.020) at entry. Mortality was 10.7%, and rate of
local complications was 7.1%. Deterioration of renal function
following PRI was suspected in 17.9% of patients.
Conclusion. PRI may improve renal function and ultimately
delay dialysis in patients with advanced renal failure. Possible
advantages must be weighed against the risk of renal failure
advancement and high procedure-related complication rate.
Renal failure attributable to atherosclerotic renal
artery stenosis (RAS) is increasingly recognized as an
important cause of renal insufficiency [1, 2]. Particularly
in the elderly population it is a major factor responsible
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for azotemia [3]. Valderrabano et al [4] have shown that
ischemic nephropathy is the primary indication for renal
replacement therapy in 21% of patients over 65 years of
age. Moreover, untreated atherosclerotic RAS tends to
progress, and observational studies have shown that RAS
with more than 60% diameter reduction progresses to oc-
clusion in 4% to 14% of cases within one year [5–8], and
kidneys supplied by stenosed arteries are at increased risk
of progressive atrophy [9].
Balloon angioplasty with or without stent placement
(percutaneous renal artery interventions; PRI) can pre-
vent renal artery occlusion [10] and has a beneficial effect
on renal function in patients with mild to moderate re-
nal dysfunction if deteriorating renal function was docu-
mented before PRI [11–20]. In patients with severe renal
failure and at high risk for dialysis, the effectiveness of
PRI remains unclear. This may be because most pub-
lished series have included only a small subset of patients
in this category [14, 15, 17, 18], and because patients with
renal failure have a higher complication rate following
PRI that unfavorably affects the risk-to-benefit ratio [11,
15].
The aim of the present uncontrolled observational co-
hort study with retrospective baseline data and prospec-
tive follow-up was to determine whether PRI can prevent
further deterioration of renal function, and thus poten-
tially delay dialysis in patients with atherosclerotic RAS
and advanced renal failure at risk for renal replacement
therapy.
METHODS
Patient selection
Between January 1995 and October 1998, 35 consecu-
tive patients with 49 atherosclerotic stenotic renal arteries
and severe renal failure [serum creatinine >300 lmol/L
(>3.4 mg/dL)] underwent primary PRI at the University
Hospital Bern (Fig. 1). Patients had angiographic docu-
mentation of a visually estimated significant atheroma-
tous renal artery stenosis based on digital subtraction
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Primary percutaneous renal artery interventions (PRI)
225 patients/298 renal arteries
108 patients/126 renal arteries
Serum creatinine
>133 µmol/L
(>1.5 mg/dL)
Serum creatinine
>300 µmol/L
(>3.4 mg/dL)
35 patients/49 renal arteries
Fig. 1. Primary percutaneous renal artery interventions in atheroscle-
rotic renal artery stenosis performed between 1995 to 1998 at the Uni-
versity Hospital Bern.
angiography by the femoral approach with the lowest
amount of nonionic, low-osmolar contrast for adequate
imaging. Views were limited to the minimum needed to
define a renal artery stenosis. Stenoses were measured
off-line using the diagnostic catheter as a reference to
define the degree of stenosis as compared to the nor-
mally appearing poststenotic segment in terms of diame-
ter reduction as a percentage. Patients had trans-stenotic
peak-to-peak pressure measurements if hemodynamic
relevance of a stenosis was in question. Trans-stenotic
pressure gradient was ≥30 mm Hg in all lesions mea-
sured. In critical stenosis (visual estimation ≥90% lu-
minal diameter reduction) pressure measurement was
renounced. Correctable causes of serum creatinine el-
evation were excluded in all cases (e.g., dehydration,
angiotensin-converting enzyme inhibitors, nonsteroidal
anti-inflammatory agents).
Study design was an uncontrolled observational cohort
study with retrospective baseline data (internal control)
and prospective follow-up. Inclusion criteria for the study
were prospective follow-up, renal function documented
for at least one year before primary PRI, minimal RAS
>60% with bilateral or >80% with unilateral PRI [21],
and kidney size >8 cm in length on the treated side. Seven
patients were excluded because of insufficient documen-
tation of renal function before PRI (N = 3), start of dial-
ysis two years before PRI (N = 1), <60% bilateral RAS
(N = 1), or <80% unilateral RAS (N = 2). The final
study population comprised 28 patients treated for 39
atherosclerotic RAS.
Nineteen patients were male and nine were female, and
the mean age was 67 ± 10 (range, 50–81) years. Dialysis
was initiated within three weeks before primary PRI in
seven patients, and scheduled in another four patients
with a glomerular filtration rate (GFR) <10 mL/min
Table 1. Demographic data of study population at entry
Baseline patient demographics
Sex (M/F) N 19/9
Creatinine lmol/L 475 ± 156a
Arterial hypertension N 28 (100%)
Baseline systolic BP mm Hg 157 ± 27
Baseline diastolic BP mm Hg 86 ± 13
No. of antihypertensive drugs/patient 2.36 ± 0.99
Hypercholesterolemia (>5.2 mmol/L) N 16 (57%)
Serum cholesterol mmol/L 6.3 ± 1.2
Smoking N 12 (43%)
Diabetes mellitus N 10 (36%)
Hypertensive and/or coronary cardiopathy N 16 (57%)
Left ventricular ejection fraction <40% N 6 (21%)
Peripheral arterial occlusive disease N 7 (25%)
Abdominal aortic aneurysm N 4 (14%)
Values are mean ± SD. BP, blood pressure.
aSerum serum creatinine level in 7 patients with far advanced renal impairment
undergoing dialysis at the time of percutaneous renal artery intervention based
on the level at start of hemodialysis; all 7 patients had a very recent start of
hemodialysis 1–3 weeks before the intervention.
(dialysants). Demographic data and comorbidity of the
study population are shown in Table 1.
Bilateral RAS >60% was documented in 11, unilateral
RAS >80% in 17 patients. Thirteen stenoses (33%) were
in an ostial location, defined as being within 5 mm from
the aortic lumen [22]. Twenty-two interventions utilized
balloon angioplasty alone, 17 required additional Palmaz
stent placement (J & J, Warren, NJ, USA). Indications for
stenting were ostial stenosis, elastic recoil >30%, resid-
ual trans-stenotic pressure gradient >10 mm Hg (peak
systolic), or residual stenosis >60% after balloon angio-
plasty alone. The PRI technique is described in detail else-
where [23]. All patients received 5000 IU heparin during
the procedure, and with one exception (thrombolysis of
renal artery occlusion), 100 mg/day aspirin thereafter.
Clinical complications were defined as the occurrence
of at least one of the following: death, myocardial infarc-
tion, and deterioration of renal function or unexpected
start of dialysis within 30 days after PRI. Other complica-
tions included hemorrhagic events (defined as bleeding
that necessitates transfusion), need for vascular surgery,
or procedural difficulties (i.e., difficulties occurring at the
puncture site, dilatation site, or in an area distal to the
dilatation site).
Assessment
Patients were prospectively evaluated on day 1, and at
3, 6, and 12 months after PRI. Review involved clinical ex-
amination, recording of blood pressure, current medical
therapy, and measurement of serum creatinine. Resteno-
sis surveillance applied renal artery duplex sonography at
any of these time points. Restenoses were verified by an-
giography and a trans-stenotic pressure gradient of more
than 30 mm Hg. Patients with restenosis warranting re-
newed catheter intervention were followed according to
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the same protocol on day 1, and 3, 6, and 12 months af-
ter last PRI. Mean follow-up for all patients was 20 ±
10 months.
Duplex examinations were performed with a 2.5–
4.5-MHz phased-array transducer (128/XP 10; Acuson,
Mountain View, CA, USA). The degree of renal artery
stenosis was determined according to validated criteria
on the basis of renal artery peak systolic velocity and the
renal aortic ratio [24, 25]. The narrowing was classified
consistent with Tullis et al [26] as follows: <60% diam-
eter reduction with peak systolic velocity <180 cm/sec
and renal aortic ratio <3.5; >60% stenosis with peak sys-
tolic velocity ≥180 cm/sec and renal aortic ratio ≥3.5; and
occlusion with no detectable flow.
Serum creatinine level served as indicator of renal func-
tion. Pre-interventional values were retrospectively ex-
tracted from patients’ charts (Division of Nephrology &
Hypertension, N = 24) or laboratory records (N = 4). At
least three serum creatinine measurements and an ob-
servation time longer than one year before PRI were re-
quired for assessment of progression of the renal failure.
Postinterventional values were prospectively collected
during subsequent follow-up visits. The effect of PRI on
the progression of renal failure was calculated by com-
paring the reciprocal slopes of serum creatinine plotted
against the time before and after intervention. Progres-
sive renal failure before primary PRI was documented
in all 28 patients included in the series. Renal outcome
was graded as follows: (1) improved (20% or greater de-
crease in the serum creatinine level versus the baseline
and a positive change in the slope of the regression line af-
ter PRI); (2) stabilized (serum creatinine level remaining
within 20% of baseline, but a positive change in the slope
of the regression line; delay of dialysis); (3) no change
(serum creatinine level remaining within 20% of baseline
and unchanged slope of regression line; PRI conferred no
benefit), or (4) deteriorated (accelerated start of dialysis
or a negative change of an already negative slope of re-
gression). Stabilization and improvement were classified
as favorable effect of PRI on renal outcome, termed as
responders. Patients with symptoms of volume overload
or high contrast exposure were considered for temporary
hemodialysis after PRI. A GFR <10 mL/min (Cockroft-
Gault formula) was assumed to indicate dialysis depen-
dency [27]. Proteinuria as a prognostic indicator was not
analyzed in this series of patients presented.
Statistical analysis
Data were analyzed applying the Splus 2000 (Math-
soft, Inc., Cambridge, UK) and StatView 4.5 (SAS Insti-
tute, Cary, NC, USA) software programs. The Wilcoxon
signed-rank test was used to analyze the effect of the
revascularization procedure on the change in slope of
one over serum creatinine versus time before and after
PRI in nondialysants and dialysants. The Mann-Whitney
U test was used to compare responders and nonrespon-
ders with regard to serum creatinine, age, blood pressure,
number of antihypertensive drugs at entry, and volume
of contrast agent used during PRI. Categorical data such
as nondialysants versus dialysants, uni- versus bilateral
intervention, diabetes, and hypercholesterolemia were
analyzed by means of contingency tables (Fisher exact
test). To identify clinical predictors of favorable renal
outcome after revascularization, Spearman rank corre-
lations were performed for the slope of reciprocal serum
creatinine values versus time, serum creatinine levels at
the time of intervention, and volume of contrast agent
used during PRI. A bivariate scattergram with display
of the regression line and 95% confidence bands was
created to plot the relationship of the slope of progres-
sion before and after PRI. A P value less than 0.05 was
considered to be statistically significant. Analysis of re-
nal function was done with a computerized least-squares
method of the reciprocal serum creatinine plot against
time [12, 17]. For those 7 patients on dialysis therapy,
the serum creatinine level at the start of renal replace-
ment therapy was considered for analysis. Measurement
of renal outcome included the change in GFR using the
Cockroft and Gault formula [27]. The difference between
the current reciprocal serum creatinine and a reciprocal
serum creatinine corresponding to a GFR of 10 mL/min
was divided by the least square linear regression for re-
ciprocal serum creatinine levels before and after PRI to
calculate the days remaining to dialysis. Cumulative pri-
mary and secondary patency rates were calculated ac-
cording to the life-table method. Sonographic patency
was defined as absence of luminal diameter narrowing
>60%.
RESULTS
Mortality and complication rates
Twenty-eight patients underwent primary PRI for
treatment of 39 atherosclerotic RAS. Eight patients un-
derwent additional 14 secondary PRI in 10 renal ar-
teries with recurrent stenosis or reocclusion. Mortality
was 10.7%; all deaths (N = 3) occurred within 30 days
of the intervention. One death was directly related to
the procedure (3.6%). The patient died four days after
PRI by cardiopulmonary arrest. There was one major
bleeding at the puncture site requiring blood transfusion,
and two false aneurysms treated by ultrasound-guided
compression (7.1%). Seventeen patients underwent
prescheduled transient hemodialysis after the procedure.
Deterioration of renal function associated with PRI was
suspected in five patients (17.9%, Table 2). One patient
with acute postinterventional renal artery occlusion un-
derwent aorto-renal bypass surgery with preservation of
renal function.
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Table 2. Outcome after primary and secondary percutaneous renal artery interventions (PRI) in 17 nondialysants and 11 dialysants of the present
series
Non-dialysants [N = 17] Dialysants [N = 11] Dialysisa
Outcome after PRI N (%) N (%) P value N (%)
Death within 30 days 1 (5.9) 2 (18.2) NS NA
Deterioration of renal function 2 (11.8) 3 (27.3) NS 4 (14.3)
No effect on renal function 1 (5.9) 4 (36.4) 0.047 4 (14.3)
Stabilization or improvement of renal function 13 (76.5) 2 (18.2) 0.006 1 (3.6)
aPatients undergoing dialysis at 12-month follow-up according to outcome after PRI; NA, not applicable.
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Fig. 2. Change in slopes of reciprocal serum creatinine 1 year before
percutaneous renal artery intervention (PRI) and 3 months after last
PRI.
Renal function
Before PRI all patients exhibited a negative slope of
the regression of reciprocal serum creatinine, indicating
progressive reduction in GFR and renal insufficiency.
The effect of PRI on the progression of renal failure as
indicated by the change in the slope before and three
months after PRI demonstrated a significant improve-
ment (Fig. 2). Mean (±SE) slopes of reciprocal serum cre-
atinine values were: 6.69 ± 0.97 L lmol−1 day−1 (×10−6)
before and 6.76 ± 3.03 L lmol−1 day−1 (×10−6) after
PRI (P = 0.0007). Renal function improved or stabilized
in 15 of the 28 patients (53.5%, Fig. 3). The mean num-
ber of antihypertensive drugs prescribed before PRI was
2.36 ± 0.99 compared with 2.43 ± 1.00 at three-month
follow-up. Subgroup analysis of 11 dialysants revealed
the following outcomes: two patients (18.2%) died within
30 days of PRI, two patients (18.2%) became indepen-
dent of dialysis, and seven patients (63.6%) remained
dependent on dialysis despite technically successful in-
tervention (Table 2). Out of 11 additional patients with
severely compromised renal function expected to become
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Fig. 3. Individual progress of renal function expressed as 1/creatinine
× 10−3 in those 15 patients with improvement or stabilization after per-
cutaneous renal artery intervention (PRI). ∗Calculated delay of dialysis
by 6 months; (dashed lines) mean value ± SEM; (dotted lines) transient
hemodialysis.
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Fig. 4. Time to dialysis as predicted by the difference between the
calculated actual glomerular filtration rate (GFR) and a GFR of 10
mL/min, and slope of GFR as given by the least square linear regres-
sion of 1/serum creatinine within 12 months of percutaneous renal artery
intervention (PRI).
permanently dependent on dialysis within 12 months, one
patient (9.1%) died, two (18.2%) experienced worsening
of renal function necessitating dialysis, and eight (72.7%)
had improved renal function and remained free of dialy-
sis after 12 months of follow-up (Fig. 4).
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Fig. 5. Relationship between changes in slope values of reciprocal
serum creatinine plot versus time before (1 year) and after (3 months)
percutaneous renal artery interventions (PRI). Three patients who died
within 30 days after PRI were excluded. (A) Non-dialysants. Mean
(±SE) slopes of reciprocal serum creatinine values were: 8.2 ± 1.4 L
lmol−1 day−1 (×10−6) before and 8.5 ± 3.8 L lmol−1 day−1 (×10−6)
after PRI (P = 0.0019). (B) Dialysants. Mean (± SE) slopes of recip-
rocal serum creatinine values were: 5.0 ± 1.4 L lmol−1 day−1 (×10−6)
before and 4.0 ± 5.0 L lmol−1 day−1 (×10−6) after PRI (P = 0.14)
Open circles, patients undergoing dialysis 3 months after PRI.
Renal outcome correlated with serum creatinine lev-
els at the time of PRI, and with reciprocal slopes of
serum creatinine levels against the time before PRI. The
mean serum creatinine level was 412 ± 86 lmol/L in
patients with improvement or stabilization (responders),
and 519 ± 170 lmol/L in patients with deterioration or
no effect on renal function (nonresponders) after PRI
(P = 0.0137). Slope values had a statistically significant
inverse relationship with renal outcome, predicting a fa-
vorable decline in the renal failure progression rate in pa-
tients with more steeply negative slope values before PRI
(r = 0.49, P = 0.02). A subgroup analysis of nondialysants
(N = 17) and dialysants (N = 11) is shown in Figure 5.
There was no statistically significant difference between
responders versus nonresponders with regard to bilateral
versus unilateral PRI, age (66 ± 11 vs. 69 ± 8), volume
of nephrotoxic contrast agent used (80 ± 64 mL, median
63 mL vs. 93 ± 69 mL, median 72 mL), blood pressure,
type and number of antihypertensives given, presence of
diabetes mellitus (3/14 patients vs. 4/11 patients), or of
hypercholesterolemia (10/15 patients vs. 3/10 patients).
Lipid-lowering drug therapy was not systematically per-
formed in the mid nineties [28].
Reintervention rate
Eight patients developed restenosis of 10 renal arter-
ies associated with deterioration of renal function during
the 12 months of follow-up after primary PRI. In all cases
catheter based reinterventions were performed, for an av-
erage of 2 ± 1 (range, 1–4) procedures per patient. The
cumulative primary patency rate was 82% at 6-month,
and 72% at 12-month follow-up. The secondary patency
rate at 12 months was 94%. Four of the eight patients
had been dependent on dialysis (N = 2) or were sched-
uled for dialysis with a GFR <10 mL/min (N = 2) before
primary PRI. Two patients became or remained indepen-
dent of dialysis up to 12 months after last PRI, one patient
died within 30 days of the reintervention, and one patient
experienced a renal artery occlusion and underwent suc-
cessful aorto-renal bypass operation with preservation of
renal function (Table 2).
Three patients experienced four renal artery reocclu-
sions (7.5%) within 30 days of the primary or secondary
interventions [1]. One patient with polycythemia vera
rubra and a GFR ∼=10 mL/min before primary PRI
experienced reocclusion after repeated angioplasty for
in-stent restenosis. The patient subsequently underwent
successful aorto-renal bypass grafting with preservation
of renal function [2]. In one patient already on dialysis
who had undergone bilateral renal artery angioplasty in
the past, duplex sonography revealed bilateral residual
stenosis (≥60%). Stents were implanted with left-sided
reocclusion 28 days later. Further intervention was re-
fused [3]. One patient with subacute renal artery occlu-
sion at entry experienced recurrent arterial occlusion.
The patient had a history of unilateral nephrectomy
22 years earlier, recurrent deep venous thrombosis, and
surgical resection of small bowel with mesenteric is-
chemia. Local thrombolysis (250,000 IU/urokinase) using
a microporous balloon (Schneider, Bu¨lach, Switzerland)
and stent implantation was performed, complicated by
initial reocclusion within 13 days, which was again suc-
cessfully thrombolyzed. A second stent thrombosis oc-
curred 5 days later with repeat local thrombolysis and a
second stent implantation. Renal function improved and
the patient was free of dialysis at 12-month follow-up.
DISCUSSION
This to our knowledge is the first study to show that
PRI facilitates the preservation of renal function and thus
extends the time off dialysis in patients with advanced
progressive renal failure. Although a high percent-
age of patients ultimately became dependent on renal
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replacement therapy, in more than half, PRI postponed
the progression of renal failure and had a favorable im-
pact on the individual’s well being. That PRI may have a
favorable effect on renal function was also supported by
a subgroup analysis of nondialysants and dialysants. The
76.5% response rate in nondialysants by far outweighed
the risks of intervention, whereas the more or less negli-
gible consequences of a deterioration in dialysants justi-
fied intervention, with 18.2% of these patients coming
off of dialysis. With high serum creatinine levels as a
predictive factor for poor renal outcome, timely recog-
nition of ischemic nephropathy is essential to enable
intervention before the patient passes “a point-of-no-
return,” with irreversible ischemic damage to the renal
parenchyma that would render improvement after in-
tervention highly unlikely. Although bilateral or unilat-
eral RAS with solitary functioning kidney are considered
as cause for global atherosclerotic renovascular disease,
termed ischemic nephropathy, a rationale also exists to
correct unilateral critical RAS in patients with renal dys-
function to prevent progressive renal disease. At least two
scenarios with potential benefit exist—either the patient
does have a diffuse renal disease with a superimposed
RAS, such as frequently observed in diabetic nephropa-
thy, or a Goldblatt hypertension type of disorder with
unilateral RAS with consecutive deteriorating hyperten-
sive nephropathy contralaterally. In this series, PRI only
had minor effects on blood pressure or number of an-
tihypertensive drugs. This argues against improvement
in renal function related to a PRI-induced medication
withdrawal.
Harden [12], Beutler [18], Watson [19], and others [16]
have suggested that significantly increased serum crea-
tinine levels are associated with poor outcomes. How-
ever, there are limitations in the interpretation of isolated
serum creatinine levels when evaluating response to PRI
[19]. Along with the absolute decline in serum creatinine
levels, a progressive deterioration in renal function just
before PRI predicts a favorable renal outcome [17, 18]. A
plausible explanation for the positive predictive value of
the preinterventional deterioration in renal function on
renal response to PRI is that a more acute change may be
an indication of ischemic damage secondary to stenosis
rather than of irreversible parenchymal damage, which
has a slow progression.
Harden et al [12] reported 34% of patients with im-
provement, and 34% with stabilization following PRI.
Serum creatinine levels ranging from 197 to 391 lmol/L
in that series were much lower than those of the present
series [12]. A similar result was presented by Muray et al,
34 of their 59 patients (57.6%) experiencing an improve-
ment in renal function defined as a positive change in
the slope of an inverse serum creatinine plot against time
after PRI. The inclusion criterion for their series was a
creatinine clearance <50 mL/min (255 ± 158 lmol/L).
The baseline serum creatinine level did not represent a
significant predictive factor for renal outcome after PRI
[17], but rapid progressive renal failure was associated
with a more favorable response. Beutler et al reported a
similar observation; comparison of 28 patients with stable
and 35 patients with declining renal function before inter-
vention revealed that the improvement in median serum
creatinine concentration was greater if renal function had
been declining than if it had been stable [18]. Specific re-
sults of PRI in relation to serum creatinine levels have
been provided by Rundback et al [14]. The benefit from
PRI was greatest in patients with only minor preinterven-
tional renal insufficiency (133–177 lmol/L, N = 19), 84%
of such patients responding to intervention. Conversely,
only 38% of patients with the highest serum creatinine
levels (>266 lmol/L, N = 8) had a favorable outcome.
In a series of 36 patients, Paulsen et al reported an im-
provement or stabilization of renal function in 60% if
the serum creatinine was >250 lmol/L. In 39% of their
patients, however, renal function worsened, and 17% of
patients ended up on dialysis within 6 months after in-
tervention [15]. Watson et al reported follow-up results
on a series of 25 patients with mild to moderate chronic
renal insufficiency (serum creatinine >1.5 mg/dL; three
patients with serum creatinine >3 mg/dL) and global ren-
ovascular obstruction (bilateral renal artery stenosis or
unilateral stenosis in the presence of a single functional
kidney). All patients exhibited a negative slope indicat-
ing progressive renal failure before PRI. After PRI the
slopes were positive in 18 patients and still negative, but
improved, in 7 patients [19].
Although there was no strong relationship between the
decline in renal function and the volume of iodinated
nephrotoxic contrast agent employed, judicious applica-
tion or the use of alternative contrast agents such as car-
bon dioxide and nonionic gadodiamide may be of benefit
[29]. Whether lipid-lowering drug therapy has a favorable
impact on the progression of renal disease as described
in a meta-analysis by Fried et al [28] cannot be answered
by the present study. Although our group of responders
included more patients with hypercholesterolemia, only
a minority had been treated with statins in the early mid
nineties.
In their meta-analysis Isles et al [16] stated that most
authors agree that recurrent stenosis is common enough
to justify follow-up monitoring and reintervention. In our
study, recurrent stenosis was treated successfully with
angioplasty, which accords with the general experience.
Applying a strategy of reintervention in patients with doc-
umented restenosis resulted in a 94% secondary patency
rate at 12-month follow-up, with primary and secondary
patency rates well in line with those of previous series
[23, 25, 30, 31]. Our results also show that renal function
may be improved, or dialysis postponed, by an aggres-
sive strategy without loss of efficiency to preserve renal
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function as previously suggested by Paulsen [15]. The
benefit of reintervention was most clearly evident in those
patients who came off dialysis, but was also seen in pa-
tients whose slope of the inverse serum creatinine had
predicted the need for dialysis within 12 months. We
presume that recurrent stenosis contributes to ischemic
nephropathy to the same extent as primary stenosis.
Although primary stenting, as many contemporary op-
erators consider the best strategy in light of ease and
likelihood of reduced restenosis, was not standard dur-
ing the study period, it is not likely that this considerably
influenced the overall result with consequently repeated
interventions and secondary stenting.
Especially noteworthy was the high complication rate
in patients with severe renal failure as compared to non-
azotemic patients. The complication rate was unusually
high in our series, with a 30-day mortality rate of 10%.
Moreover, these patients had a 7% rate of local compli-
cations, a 17% rate of intervention-related deterioration
of renal function, and a 7% rate of reocclusion. Data pre-
viously published by our group [23, 32] suggest that these
problems are directly related to the high rate of cardio-
vascular morbidity in this particular subgroup of severely
azotemic patients, a finding reflected in similar complica-
tion rates reported by others. Pattynama et al described a
complication rate in azotemic patients of 15% versus only
6% in nonazotemic patients [11]. Paulsen et al reported
that complications were frequent and many patients ul-
timately required dialysis in a subgroup of patients pre-
senting with serum creatinine levels >250 lmol/L [15].
Deterioration of renal function can reflect progression of
nephropathy, but an accelerated slope of progression af-
ter PRI is probably related to cholesterol or atheroemboli
released during the procedure or to the nephrotoxicity of
the contrast medium used [33, 34]. Harden et al [12] de-
scribed five patients (16%) with accelerated progression,
three of whom had a serum creatinine >400 lmol/L and
became dialysis dependent. The series published by Beut-
ler et al [18] had a 6% rate of renal artery injury and an
8% rate of cholesterol embolism with renal dysfunction.
The present nonrandomized uncontrolled observa-
tional cohort study possesses the limitations inherent in
such a design. The possibility that changes in antihy-
pertensive medications could have effected the outcome
cannot be ruled out. Thus, the specific influence of the
treatment on the subsequent clinical course cannot be
assessed separately. Although the series did not include
a separate control group of untreated patients, the retro-
spective course of each patient before treatment served
as an individual control. In most patients with chronic re-
nal insufficiency serum creatinine levels tend to increase
spontaneously [35, 36], and we assume that a negative
linear relation exists for the reciprocal of serum creati-
nine plotted against time in patients with atherosclerotic
renovascular disease.
CONCLUSION
Whether and for which patients with advanced renal
failure PRI can be cost-effective with low risks can be
answered only in randomized studies. However, some
conclusions can be drawn from this observational study
where it is notoriously difficult to obtain hard and fast
results because of the nature of the patient population
and the difficulty of undertaking controlled intervention.
First, the complication rate is higher in azotemic as com-
pared to nonazotemic patients and must be considered if
an intervention is planned. Second, ischemic nephropa-
thy is a complex disease that involves not only renal ar-
teries, but is also associated with lipid abnormalities or
hypertensive nephroangiosclerosis. The finding that PRI
can control progression of renal failure clearly indicates
that stenosis plays a role, but it does not exclude the rel-
evance of other contributing factors. Third, patients pre-
senting close to the estimated time for initiation of dialysis
treatment seem to be least likely to benefit from revas-
cularization, whereas those with recent progressive loss
of renal function are more likely to have a favorable re-
nal outcome after PRI. Further arguments may be drawn
from patients expected to become permanently depen-
dent on dialysis within 12 months with the Cockroft-
Gault formula as accepted tool to predict renal outcome
[27].
Reprint requests to I. Baumgartner, M.D., Swiss Cardiovascular Cen-
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